Amicus Therapeutics Presents Additional 6-Month Results from Phase 3 Fabry Monotherapy Study at LDN World Symposium

[at noodls] – Conference Call Today at 11:30am ET CRANBURY, N.J. and ORLANDO, Fla., Feb. 15, 2013 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq:FOLD), today announced additional 6-month (Stage 1) results from the … more

View todays social media effects on FOLD

View the latest stocks trending across Twitter. Click to view dashboard

See who Amicus is hiring next, click here to view